Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Osteosarcoma is the most common primary bone malignancy in adolescents. Its high
propensity to metastasize is the leading cause for treatment failure and poor prognosis …

Chemical protein modification has emerged as an invaluable tool for the development of
modified proteins. The complementary use of both genetic and chemical methods has …

Combining the selective targeting of tumor cells through antigen-directed recognition and
potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in …

G-protein-coupled receptors (GPCRs) are activated by a diverse range of ligands, from large
proteins and proteases to small peptides, metabolites, neurotransmitters and ions. They are …

The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)
blasts with the bone marrow microenvironment regulates self-renewal, growth signaling, as …

Systemic chemotherapy, the current standard of care for the treatment of cancer, is rarely
curative and is often accompanied by debilitating side effects. Targeted drug delivery stands …

Bioconjugates represent an emerging class of medicines, which offer therapeutic
opportunities overtaking those of the individual components. Many novel bioconjugates …

The incorporation of aldehyde handles into proteins, and subsequent chemical reactions
thereof, is rapidly proving to be an effective way of generating homogeneous, covalently …

Antibody conjugates are important in many areas of medicine and biological research, and
antibody–drug conjugates (ADCs) are becoming an important next generation class of …